All In Biotech

NDA 014134 · Baxter Hlthcare Corp

Protopam Chloride

Pralidoxime Chloride · Injection

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jan 15, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Mar 11, 1964

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

1 Phase 3, 1 recruiting

FAERS reports

26

15 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

INDICATIONS AND USAGE PROTOPAM Chloride is indicated as an antidote: (1) in the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and (2) in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 11, 1964 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • PROTOPAM CHLORIDE · PRALIDOXIME CHLORIDE 1GM/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pralidoxime Chloride" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • accidental exposure6
  • expired drug administered5
  • injection site injury4
  • drug ineffective3
  • accidental exposure to product2
  • expired product administered2
  • extrapyramidal disorder2
  • injection site pain2
  • mental disorder due to a general medical condition2
  • peripheral swelling2
  • agitation1
  • agranulocytosis1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20102
20114
20122
20134
20144
20151
20172
20192
20201
20213
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.